SOPHiA GENETICS SA
SOPH
Positions held
Your positionsSOPH isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $621.43M | Enterprise value | $575.60M | Trailing P/E | — | Forward P/E | -14.60 |
| PEG | — | Price / book | 7.48 | Beta | 0.95 | Dividend yield | 0.00% |
| Revenue growth | 27.2% | Earnings growth | — | Gross margin | 66.6% | Operating margin | -86.0% |
| Profit margin | -93.9% | ROE | -101.2% | ROA | -24.5% | Debt / equity | 0.74 |
| Current ratio | 2.69 | Free cash flow | -$25.66M | Analyst recommendation | none | Mean target | $9.75 |
| 52w high | $8.98 | 52w low | $3.75 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $23.3M | $21.7M | $21.7M | $19.5M | $18.3M | — |
| Op margin | -86.0% | -79.7% | -85.3% | -91.8% | -100.9% | — |
| Net income | -$22.4M | -$19.3M | -$19.2M | -$20.0M | -$22.4M | — |
| Gross margin | 64.6% | 68.0% | 67.7% | 66.3% | 67.0% | — |
| Gross profit | $15.1M | $14.7M | $14.7M | $12.9M | $12.3M | — |
| Operating income | -$20.1M | -$17.3M | -$18.5M | -$17.9M | -$18.5M | — |
- Revenue +7% vs prior quarter ($23M vs $22M).
- Gross margin 64.6% (was 68% prior quarter).
- Operating margin compressed to -86%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $77.3M | $65.2M | $62.4M | $47.6M |
| Op margin | -91.8% | -102.1% | -120.0% | -184.7% |
| Net income | -$79.0M | -$62.5M | -$79.0M | -$87.4M |
| Gross margin | 67.4% | 67.4% | 68.8% | 65.7% |
| Gross profit | $52.1M | $43.9M | $42.9M | $31.3M |
| Operating income | -$70.9M | -$66.6M | -$74.8M | -$87.8M |
Headlines — positive tone
• [OK · fundamentals] Sophia Genetics SA (SOPH) (Q2 2026) Earnings Call Highlights: Record Revenue Growth and ...
News
2026-10-08 · Sophia Genetics, Myriad Genetics Collaborate on Prostate Cancer Biomarker
2026-09-18 · SOPHiA GENETICS (SOPH) Moves 7.0% Higher: Will This Strength Last?
2026-09-04 · SOPHiA GENETICS (SOPH) Stock Sees Modest Fair Value Lift After Q2 Guidance Raise
2026-08-27 · When Unusual Volume Isn't Noise: 3 Small-Caps Sending Signals
2026-08-11 · SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript
2026-08-08 · AstraZeneca (LSE:AZN) Signs Two Cancer Diagnostics Deals To Widen Patient Access
2026-08-05 · SOPHiA GENETICS partners with AstraZeneca for oncology diagnostics
2026-08-05 · SOPHiA GENETICS partners with AstraZeneca for oncology diagnostics
Price (daily)
Full chart · RSI · MACD · patterns